Cite
HARVARD Citation
Brahmer, J. et al. (n.d.). Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet oncology. 18 (12), pp. 1600-1609. [Online].